RECURSION PHARMACEUTICALS

Recursion CFO’s steady sales of $3.20‑$3.40 shares signal caution—investors should watch quarterly earnings and product updates before buying.

CEO Khan Najat’s recent 22,408‑share sale on a quiet day shows a structured, moderate exit—no distress, just personal portfolio balance for Recursion.

Insider sales at Recursion: CFO sells 25k shares at $3.16, indicating steady liquidity strategy amid market volatility. Learn what it means for investors.

Insight: Borgeson Blake’s July 7 insider sale of 40,000 Recursion shares—priced at $3.96—signals cautious liquidity amid rising buzz, urging investors to watch short‑term volatility and the company’s AI‑driven drug pipeline for long‑term confidence.

Recursion insider buying surge signals confidence: board member Dar Zavain adds shares at a 52‑week low, hinting at future pipeline catalysts and a potential rebound.